GlassScriptPhysician profile
Michael S Bodin
NPI 1376743427
$7,753.99
in general payments reported to CMS, 2019-2025
46 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $544 · 2021: $1,136 · 2022: $1,266 · 2023: $1,462 · 2024: $1,074 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,712 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.03 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,214.54 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $960.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $677.66 | 2019-2024 | Jardiance, Synjardy, Ofev |
| Novo Nordisk INC | $459.24 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $453.34 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $389.93 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Janssen Pharmaceuticals, INC | $375.38 | 2019-2022 | |
| Amgen INC. | $336.97 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $329.41 | 2019-2023 | Belsomra, Steglatro, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $323.07 | 2021-2025 | |
| Abbott Laboratories | $285.20 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $261.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $165.86 | 2019-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $160.57 | 2019-2024 | Trintellix |
| Allergan, INC. | $155.38 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.